Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Digestive Disorder

PUBLISHER: Markets & Data | PRODUCT CODE: 1781186

Cover Image

PUBLISHER: Markets & Data | PRODUCT CODE: 1781186

Global Liver Disease Therapeutics Market Assessment, By Disease Type, By Therapy Type, By Drug Class, By Distribution Channel, By Region, Opportunities and Forecast, 2018-2032F

PUBLISHED:
PAGES: 229 Pages
DELIVERY TIME: 3-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel Printable (Single User License)
USD 4800
PDF & Excel Printable (Corporate License)
USD 6000
PDF & Excel Printable (Custom Research License)
USD 8500

Add to Cart

Description

Table of Contents

List of Tables

Global liver disease therapeutics market is projected to witness a CAGR of 7.11% during the forecast period 2025-2032, growing from USD 25.67 billion in 2024 to USD 44.47 billion in 2032. The liver disease therapeutics market continues to develop at a rapid rate. This development is largely attributed to the increasing incidence of liver disease including hepatitis, fatty liver and cirrhosis due to the growing rate of unhealthy diets, alcohol consumption, and obesity. Many patients are diagnosed earlier due to better screening programs increasing their access to treatment rights away. The R&D spending from pharmaceutical companies continues to increase and is in part driving growth of the market due to increased access to new, effective therapy options. The advances in diagnostics and the availability of targeted therapies that do not require invasive testing are increasing rapidly and creating new opportunities. Governments are investing in public health follow-up and awareness of liver disease which leads to early diagnosis and prevention of liver disease.

Pharmaceutical companies are also investing more in research and development which enhances the prospect of bringing forward new effective therapies to the market. Additionally, e-pharmacies and more accessible allied health care provide better access to needed drug therapies. Overall, demand is strong, there is continued innovation, and government policies will continue to support the market. The above factors will continue to support the growth of the market.

For instance, in April 2025, Indian Union Home Minister spoke at a World Liver Day program conducted by the Institute of Liver and Biliary Sciences (ILBS) in India and noted the need for liver health recognition and programs, such as the HEALED scheme, to promote countrywide awareness. In another instance, in April 2025, Indian Union Health Minister led a Liver Health Pledge Ceremony during a health camp organized by the Ministry in collaboration with FSSAI and the Institute of Liver and Biliary Sciences, In India.

Impact of Unhealthy Lifestyles on the Rising Prevalence of Liver Diseases

Liver diseases are rising worldwide as people continue to follow poor lifestyle habits. The combination of sedentary habits and a diet that has high saturated fats and sugar is a big part of the epidemic rise of non-alcoholic fatty liver disease (NAFLD) and its potential for progression. High alcohol consumption is still one of the biggest players in the development of alcoholic liver disease and thus cirrhosis. Smoking and drug use can also worsen liver injury, which commonly leads to obesity, along with insulin resistance and metabolic syndrome, a major risk factors for chronic liver disease. With the increasing prevalence of lifestyle habits across urban populations, liver disease prevalence will continue to increase alongside lifestyle diseases. It is going to require coordinated public health action for prevention, early diagnosis, and treatment of disease.

For instance, in 2023, the National Vital Statistics System - Mortality Data (CDC WONDER) reported 28,632 deaths due to alcoholic liver disease in the United States, equating to 8.5 deaths per 100,000 population.

Technological Innovations Driving Growth in Liver Disease Therapeutics

Technological advancement is working as a catalyst on liver therapeutics market. New tools help detect liver problems earlier. Non-invasive diagnostic tools or methods are replacing painful biopsies. Imaging techniques have become more accurate and detailed or precise. It allows doctors to see liver damage clearly and quickly. Targeted drug delivery systems are improving treatment outcomes. Medications now reach the liver more effectively. This leads to better results with fewer side effects. Biotechnology is also bringing new therapies to the market. These are designed to treat the disease at its source. Digital health platforms help the doctors to monitor patients remotely. Patients can track symptoms and share the updates in real time. Artificial intelligence (AI) is now used to study disease patterns. Interference of AI is transforming the treatment and diagnosis rapidly. AI also helps doctors choose the best treatment i.e. personalized treatment. Telemedicine is expanding the treatment access to underdeveloped areas. Furthermore, the patients in remote areas can consult liver specialists. These technologies make care faster, safer, and more effective. As innovations continue, the liver disease therapeutics market is expected to grow steadily.

For instance, in May 2025, The Vall d'Hebron Institute of Oncology launched a tool called The GIST that runs on artificial intelligence and has been designed to automate the detection and monitoring of liver tumors. It aims to ultimately increase speed and accuracy in the diagnosis of liver disease.

Hepatitis Dominates the Liver Disease Therapeutics Market

Hepatitis remains the largest segment within the liver disease therapeutics market, and it is due to its high global burden and clinical relevance. Hepatitis C is called a silent epidemic, its severity pushes the infection to chronic conditions like cirrhosis, hepatic failure, or hepatocellular carcinoma. However, the advent of direct-acting antivirals (DAAs), treatment options are becoming increasingly better, creating acceptable cure rates over shorter treatment regimens, generally with better safety profiles. Awareness of screening programs and public health responses are helping in timely diagnosis and eventually timely treatment. Additionally, pharmaceutical companies have made capital investments into further drug development including fixed-dose combinations or pan-genotypic regimens that allow access to treatment and better treatment patterns. With continued efforts from health systems and the pharmaceutical industry, the Hepatitis C segment will continue to be the largest market share of the liver disease therapeutics market in the years to come.

For instance, according to the data published in the Viral Hepatitis Surveillance Report - United States, 2023 reported an estimated 69,000 acute hepatitis C infections and over 101,000 newly diagnosed chronic cases across the United States, along with more than 11,000 related deaths. In another instance, in May 2025, Gilead Sciences, Inc. presented final Phase 3 data on bulevirtide monotherapy at the EASL Congress, showing 36% of chronic hepatitis D patients maintained undetectable viral levels nearly two years after treatment.

North America Dominates the Liver Disease Therapeutics Market

North America continues to dominate the liver disease therapeutics market due to its solid healthcare infrastructure, greater presence of global pharmaceutical companies, and improved public awareness regarding liver health. Not only is the region supporting innovation in therapeutics for hepatitis, fatty liver disease, cirrhosis, and liver cancer, but it is also fostering action in treating liver disease. Supported by a strong pipeline in research and development, both the United States and Canada have a significant portfolio from all the major pharmaceutical companies including the biggest players (e.g. Pfizer, AbbVie, and Johnson & Johnson), which all have a sustained engagement in drug innovation and continuous clinical trials for liver disease. Furthermore, the existing advanced liver disease therapeutics, extensive use of established prescription, over-the-counter medications, and growing access to medication through e-pharmacy, all around the U.S. and Canada, support the liver disease therapeutics market. Additional government health policies and initiatives such as national screening programs, support the promotion of early diagnosis, case detection, and access to timely treatment for patients. The rise in demand for effective therapy options is driven by the high rate of individuals with obesity and problematic alcohol consumption, or those with liver disease because of lifestyle risk factors. Companies in North America frequently engage in mergers and acquisitions and new product launches to strengthen their market position and introduce advanced treatments.

For instance, on November 2024, Gilead Sciences, Inc. presented new research across major liver disease indications at the American Association for the Study of Liver Diseases (AASLD) 2024 meeting.

Impact of U.S. Tariffs on Global Liver Disease Therapeutics Market

Tariffs imposed on imported materials lead to higher costs for the process of manufacturing. As costs increase, they are often passed to the end user in the form of a price increase on treatment.

Tariffs can hinder the consistent and reliable supply of Active Pharmaceutical Ingredients (APIs) from primary manufacturing countries.

Companies may select to work with domestic suppliers or alternate suppliers, which affect time.

Smaller participants may work off of thinner margins, which warrants the potential for competition to lower in the market.

Key Players Landscape and Outlook

The liver disease therapeutics market is experiencing considerable activity from the major pharmaceutical companies in the area with a commitment to establish their position through new products and actions in the area. This includes companies including GSK plc, AbbVie Inc., Pfizer Inc., Johnson & Johnson Services, Inc., and Novartis AG who are funding research, clinical trials, and acquisitions to new treatment option. The focus continues to evolve to targeted therapies, biologics, and advanced medicine that will treat patients with chronic liver conditions including Non-Alcoholic Steatohepatitis (NASH), cirrhosis, and liver cancer. In addition, there are many biotech companies developing new and novel solutions to the competitive landscape. Therefore, the prospects for the market are positive given the increasing patient awareness, growing regulatory pathways favoring innovation, and increasing global need and demand for effective liver disease therapy.

For instance, in July 2025, GSK plc completed the acquisition of efimosfermin, a potential best-in-class specialty medicine aimed at treating and preventing the progression of steatotic liver disease (SLD).

Show more
Product Code: MX13844

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. Global Liver Disease Therapeutics Market Outlook, 2018-2032F

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Disease Type
      • 5.2.1.1. Hepatitis
      • 5.2.1.2. Non-Alcoholic Fatty Liver Disease
      • 5.2.1.3. Autoimmune Liver Diseases
      • 5.2.1.4. Liver Cancer
      • 5.2.1.5. Genetic Disorders
    • 5.2.2. By Therapy Type
      • 5.2.2.1. Antiviral Drugs
      • 5.2.2.2. Immunosuppressants
      • 5.2.2.3. Vaccines
      • 5.2.2.4. Immunoglobulins
      • 5.2.2.5. Others
    • 5.2.3. By Drug Class
      • 5.2.3.1. Antiviral Agents
      • 5.2.3.2. Biologics
      • 5.2.3.3. Small Molecule Drugs
    • 5.2.4. By Distribution Channel
      • 5.2.4.1. Hospital Pharmacies
      • 5.2.4.2. Retail Pharmacies
      • 5.2.4.3. Online Pharmacies
    • 5.2.5. By Region
      • 5.2.5.1. North America
      • 5.2.5.2. Europe
      • 5.2.5.3. Asia-Pacific
      • 5.2.5.4. South America
      • 5.2.5.5. Middle East and Africa
    • 5.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 5.3. Market Map Analysis, 2024
    • 5.3.1. By Disease Type
    • 5.3.2. By Therapy Type
    • 5.3.3. By Drug Class
    • 5.3.4. By Distribution Channel
    • 5.3.5. By Region

6. North America Liver Disease Therapeutics Market Outlook, 2018-2032F

  • 6.1. Market Size Analysis & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share Analysis & Forecast
    • 6.1.2. By Disease Type
      • 6.1.2.1. Hepatitis
      • 6.1.2.2. Non-Alcoholic Fatty Liver Disease
      • 6.1.2.3. Autoimmune Liver Diseases
      • 6.1.2.4. Liver Cancer
      • 6.1.2.5. Genetic Disorders
    • 6.1.3. By Therapy Type
      • 6.1.3.1. Antiviral Drugs
      • 6.1.3.2. Immunosuppressants
      • 6.1.3.3. Vaccines
      • 6.1.3.4. Immunoglobulins
      • 6.1.3.5. Others
    • 6.1.4. By Drug Class
      • 6.1.4.1. Antiviral Agents
      • 6.1.4.2. Biologics
      • 6.1.4.3. Small Molecule Drugs
    • 6.1.5. By Distribution Channel
      • 6.1.5.1. Hospital Pharmacies
      • 6.1.5.2. Retail Pharmacies
      • 6.1.5.3. Online Pharmacies
    • 6.1.6. By Country Share
      • 6.1.6.1. United States
      • 6.1.6.2. Canada
      • 6.1.6.3. Mexico
  • 6.3. Country Market Assessment
    • 6.3.1. United States Liver Disease Therapeutics Market Outlook, 2018-2032F*
      • 6.3.1.1. Market Size Analysis & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share Analysis & Forecast
        • 6.3.1.2.1. By Disease Type
          • 6.3.1.2.1.1. Hepatitis
          • 6.3.1.2.1.2. Non-Alcoholic Fatty Liver Disease
          • 6.3.1.2.1.3. Autoimmune Liver Diseases
          • 6.3.1.2.1.4. Liver Cancer
          • 6.3.1.2.1.5. Genetic Disorders
        • 6.3.1.2.2. By Therapy Type
          • 6.3.1.2.2.1. Antiviral Drugs
          • 6.3.1.2.2.2. Immunosuppressants
          • 6.3.1.2.2.3. Vaccines
          • 6.3.1.2.2.4. Immunoglobulins
          • 6.3.1.2.2.5. Others
        • 6.3.1.2.3. By Drug Class
          • 6.3.1.2.3.1. Antiviral Agents
          • 6.3.1.2.3.2. Biologics
          • 6.3.1.2.3.3. Small Molecule Drugs
        • 6.3.1.2.4. By Distribution Channel
          • 6.3.1.2.4.1. Hospital Pharmacies
          • 6.3.1.2.4.2. Retail Pharmacies
          • 6.3.1.2.4.3. Online Pharmacies
    • 6.3.2. Canada
    • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Liver Disease Therapeutics Market Outlook, 2018-2032F

  • 7.1. Germany
  • 7.2. France
  • 7.3. Italy
  • 7.4. United Kingdom
  • 7.5. Russia
  • 7.6. Netherlands
  • 7.7. Spain
  • 7.8. Turkey
  • 7.9. Poland

8. Asia-Pacific Liver Disease Therapeutics Market Outlook, 2018-2032F

  • 8.1. India
  • 8.2. China
  • 8.3. Japan
  • 8.4. Australia
  • 8.5. Vietnam
  • 8.6. South Korea
  • 8.7. Indonesia
  • 8.8. Philippines

9. South America Liver Disease Therapeutics Market Outlook, 2018-2032F

  • 9.1. Brazil
  • 9.2. Argentina

10. Middle East and Africa Liver Disease Therapeutics Market Outlook, 2018-2032F

  • 10.1. Saudi Arabia
  • 10.2. UAE
  • 10.3. South Africa

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

  • 15.1. Market Drivers
  • 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

18. Case Studies

19. Competitive Landscape

  • 19.1. Competition Matrix of Top 5 Market Leaders
  • 19.2. SWOT Analysis for Top 5 Players
  • 19.3. Key Players Landscape for Top 10 Market Players
    • 19.3.1. GSK plc
      • 19.3.1.1. Company Details
      • 19.3.1.2. Key Management Personnel
      • 19.3.1.3. Products and Services
      • 19.3.1.4. Financials (As Reported)
      • 19.3.1.5. Key Market Focus and Geographical Presence
      • 19.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
    • 19.3.2. AbbVie Inc.
    • 19.3.3. Bristol-Myers Squibb Company
    • 19.3.4. F. Hoffmann-La Roche Ltd
    • 19.3.5. Takeda Pharmaceutical Company Limited
    • 19.3.6. Johnson & Johnson Services, Inc.
    • 19.3.7. Merck & Co., Inc.
    • 19.3.8. Novartis AG
    • 19.3.9. Pfizer Inc.
    • 19.3.10. Sanofi S.A.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

20. Strategic Recommendations

21. About Us and Disclaimer

Show more
Product Code: MX13844

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Liver Disease Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 2. Global Liver Disease Therapeutics Market Share (%), By Disease Type, 2018-2032F
  • Figure 3. Global Liver Disease Therapeutics Market Share (%), By Therapy Type, 2018-2032F
  • Figure 4. Global Liver Disease Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 5. Global Liver Disease Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 6. Global Liver Disease Therapeutics Market Share (%), By Region, 2018-2032F
  • Figure 7. North America Liver Disease Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 8. North America Liver Disease Therapeutics Market Share (%), By Disease Type, 2018-2032F
  • Figure 9. North America Liver Disease Therapeutics Market Share (%), By Therapy Type, 2018-2032F
  • Figure 10. North America Liver Disease Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 11. North America Liver Disease Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 12. North America Liver Disease Therapeutics Market Share (%), By Country, 2018-2032F
  • Figure 13. United States Liver Disease Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 14. United States Liver Disease Therapeutics Market Share (%), By Disease Type, 2018-2032F
  • Figure 15. United States Liver Disease Therapeutics Market Share (%), By Therapy Type, 2018-2032F
  • Figure 16. United States Liver Disease Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 17. United States Liver Disease Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 18. Canada Liver Disease Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 19. Canada Liver Disease Therapeutics Market Share (%), By Disease Type, 2018-2032F
  • Figure 20. Canada Liver Disease Therapeutics Market Share (%), By Therapy Type, 2018-2032F
  • Figure 21. Canada Liver Disease Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 22. Canada Liver Disease Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 23. Mexico Liver Disease Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 24. Mexico Liver Disease Therapeutics Market Share (%), By Disease Type, 2018-2032F
  • Figure 25. Mexico Liver Disease Therapeutics Market Share (%), By Therapy Type, 2018-2032F
  • Figure 26. Mexico Liver Disease Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 27. Mexico Liver Disease Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 28. Europe Liver Disease Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 29. Europe Liver Disease Therapeutics Market Share (%), By Disease Type, 2018-2032F
  • Figure 30. Europe Liver Disease Therapeutics Market Share (%), By Therapy Type, 2018-2032F
  • Figure 31. Europe Liver Disease Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 32. Europe Liver Disease Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 33. Europe Liver Disease Therapeutics Market Share (%), By Country, 2018-2032F
  • Figure 34. Germany Liver Disease Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 35. Germany Liver Disease Therapeutics Market Share (%), By Disease Type, 2018-2032F
  • Figure 36. Germany Liver Disease Therapeutics Market Share (%), By Therapy Type, 2018-2032F
  • Figure 37. Germany Liver Disease Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 38. Germany Liver Disease Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 39. France Liver Disease Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 40. France Liver Disease Therapeutics Market Share (%), By Disease Type, 2018-2032F
  • Figure 41. France Liver Disease Therapeutics Market Share (%), By Therapy Type, 2018-2032F
  • Figure 42. France Liver Disease Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 43. France Liver Disease Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 44. Italy Liver Disease Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 45. Italy Liver Disease Therapeutics Market Share (%), By Disease Type, 2018-2032F
  • Figure 46. Italy Liver Disease Therapeutics Market Share (%), By Therapy Type, 2018-2032F
  • Figure 47. Italy Liver Disease Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 48. Italy Liver Disease Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 49. United Kingdom Liver Disease Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 50. United Kingdom Liver Disease Therapeutics Market Share (%), By Disease Type, 2018-2032F
  • Figure 51. United Kingdom Liver Disease Therapeutics Market Share (%), By Therapy Type, 2018-2032F
  • Figure 52. United Kingdom Liver Disease Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 53. United Kingdom Liver Disease Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 54. Russia Liver Disease Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 55. Russia Liver Disease Therapeutics Market Share (%), By Disease Type, 2018-2032F
  • Figure 56. Russia Liver Disease Therapeutics Market Share (%), By Therapy Type, 2018-2032F
  • Figure 57. Russia Liver Disease Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 58. Russia Liver Disease Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 59. Netherlands Liver Disease Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 60. Netherlands Liver Disease Therapeutics Market Share (%), By Disease Type, 2018-2032F
  • Figure 61. Netherlands Liver Disease Therapeutics Market Share (%), By Therapy Type, 2018-2032F
  • Figure 62. Netherlands Liver Disease Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 63. Netherlands Liver Disease Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 64. Spain Liver Disease Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 65. Spain Liver Disease Therapeutics Market Share (%), By Disease Type, 2018-2032F
  • Figure 66. Spain Liver Disease Therapeutics Market Share (%), By Therapy Type, 2018-2032F
  • Figure 67. Spain Liver Disease Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 68. Spain Liver Disease Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 69. Turkey Liver Disease Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 70. Turkey Liver Disease Therapeutics Market Share (%), By Disease Type, 2018-2032F
  • Figure 71. Turkey Liver Disease Therapeutics Market Share (%), By Therapy Type, 2018-2032F
  • Figure 72. Turkey Liver Disease Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 73. Turkey Liver Disease Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 74. Poland Liver Disease Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 75. Poland Liver Disease Therapeutics Market Share (%), By Disease Type, 2018-2032F
  • Figure 76. Poland Liver Disease Therapeutics Market Share (%), By Therapy Type, 2018-2032F
  • Figure 77. Poland Liver Disease Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 78. Poland Liver Disease Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 79. Asia-Pacific Liver Disease Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 80. Asia-Pacific Liver Disease Therapeutics Market Share (%), By Disease Type, 2018-2032F
  • Figure 81. Asia-Pacific Liver Disease Therapeutics Market Share (%), By Therapy Type, 2018-2032F
  • Figure 82. Asia-Pacific Liver Disease Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 83. Asia-Pacific Liver Disease Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 84. Asia-Pacific Liver Disease Therapeutics Market Share (%), By Country, 2018-2032F
  • Figure 85. India Liver Disease Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 86. India Liver Disease Therapeutics Market Share (%), By Disease Type, 2018-2032F
  • Figure 87. India Liver Disease Therapeutics Market Share (%), By Therapy Type, 2018-2032F
  • Figure 88. India Liver Disease Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 89. India Liver Disease Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 90. China Liver Disease Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 91. China Liver Disease Therapeutics Market Share (%), By Disease Type, 2018-2032F
  • Figure 92. China Liver Disease Therapeutics Market Share (%), By Therapy Type, 2018-2032F
  • Figure 93. China Liver Disease Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 94. China Liver Disease Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 95. Japan Liver Disease Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 96. Japan Liver Disease Therapeutics Market Share (%), By Disease Type, 2018-2032F
  • Figure 97. Japan Liver Disease Therapeutics Market Share (%), By Therapy Type, 2018-2032F
  • Figure 98. Japan Liver Disease Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 99. Japan Liver Disease Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 100. Australia Liver Disease Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 101. Australia Liver Disease Therapeutics Market Share (%), By Disease Type, 2018-2032F
  • Figure 102. Australia Liver Disease Therapeutics Market Share (%), By Therapy Type, 2018-2032F
  • Figure 103. Australia Liver Disease Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 104. Australia Liver Disease Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 105. Vietnam Liver Disease Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 106. Vietnam Liver Disease Therapeutics Market Share (%), By Disease Type, 2018-2032F
  • Figure 107. Vietnam Liver Disease Therapeutics Market Share (%), By Therapy Type, 2018-2032F
  • Figure 108. Vietnam Liver Disease Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 109. Vietnam Liver Disease Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 110. South Korea Liver Disease Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 111. South Korea Liver Disease Therapeutics Market Share (%), By Disease Type, 2018-2032F
  • Figure 112. South Korea Liver Disease Therapeutics Market Share (%), By Therapy Type, 2018-2032F
  • Figure 113. South Korea Liver Disease Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 114. South Korea Liver Disease Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 115. Indonesia Liver Disease Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 116. Indonesia Liver Disease Therapeutics Market Share (%), By Disease Type, 2018-2032F
  • Figure 117. Indonesia Liver Disease Therapeutics Market Share (%), By Therapy Type, 2018-2032F
  • Figure 118. Indonesia Liver Disease Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 119. Indonesia Liver Disease Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 120. Philippines Liver Disease Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 121. Philippines Liver Disease Therapeutics Market Share (%), By Disease Type, 2018-2032F
  • Figure 122. Philippines Liver Disease Therapeutics Market Share (%), By Therapy Type, 2018-2032F
  • Figure 123. Philippines Liver Disease Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 124. Philippines Liver Disease Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 125. South America Liver Disease Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 126. South America Liver Disease Therapeutics Market Share (%), By Disease Type, 2018-2032F
  • Figure 127. South America Liver Disease Therapeutics Market Share (%), By Therapy Type, 2018-2032F
  • Figure 128. South America Liver Disease Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 129. South America Liver Disease Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 130. South America Liver Disease Therapeutics Market Share (%), By Country, 2018-2032F
  • Figure 131. Brazil Liver Disease Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 132. Brazil Liver Disease Therapeutics Market Share (%), By Disease Type, 2018-2032F
  • Figure 133. Brazil Liver Disease Therapeutics Market Share (%), By Therapy Type, 2018-2032F
  • Figure 134. Brazil Liver Disease Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 135. Brazil Liver Disease Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 136. Argentina Liver Disease Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 137. Argentina Liver Disease Therapeutics Market Share (%), By Disease Type, 2018-2032F
  • Figure 138. Argentina Liver Disease Therapeutics Market Share (%), By Therapy Type, 2018-2032F
  • Figure 139. Argentina Liver Disease Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 140. Argentina Liver Disease Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 141. Middle East & Africa Liver Disease Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 142. Middle East & Africa Liver Disease Therapeutics Market Share (%), By Disease Type, 2018-2032F
  • Figure 143. Middle East & Africa Liver Disease Therapeutics Market Share (%), By Therapy Type, 2018-2032F
  • Figure 144. Middle East & Africa Liver Disease Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 145. Middle East & Africa Liver Disease Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 146. Middle East & Africa Liver Disease Therapeutics Market Share (%), By Country, 2018-2032F
  • Figure 147. Saudi Arabia Liver Disease Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 148. Saudi Arabia Liver Disease Therapeutics Market Share (%), By Disease Type, 2018-2032F
  • Figure 149. Saudi Arabia Liver Disease Therapeutics Market Share (%), By Therapy Type, 2018-2032F
  • Figure 150. Saudi Arabia Liver Disease Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 151. Saudi Arabia Liver Disease Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 152. UAE Liver Disease Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 153. UAE Liver Disease Therapeutics Market Share (%), By Disease Type, 2018-2032F
  • Figure 154. UAE Liver Disease Therapeutics Market Share (%), By Therapy Type, 2018-2032F
  • Figure 155. UAE Liver Disease Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 156. UAE Liver Disease Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 157. South Africa Liver Disease Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 158. South Africa Liver Disease Therapeutics Market Share (%), By Disease Type, 2018-2032F
  • Figure 159. South Africa Liver Disease Therapeutics Market Share (%), By Therapy Type, 2018-2032F
  • Figure 160. South Africa Liver Disease Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 161. South Africa Liver Disease Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 162. By Disease Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 163. By Therapy Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 164. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 165. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!